Disease · MONDO_0007827
inclusion body myositis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. inclusion body myositis. Diseases, record MONDO_0007827. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007827
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Distal Myopathy with Rimmed Vacuoles (DMRV), Distal myopathy, Nonaka type, HIBM, Hereditary Inclusion Body Myopathy, IBM, IBM-3, IBM2, Myositis, Inclusion Body, Nonaka Myopathy, Sporadic Inclusion Body Myositis, inclusion body myopathy 2, inclusion body myopathy 3, sIBM
- Open Targets
- Highest stage of its drugs
- Phase 3, for 3 of its 19 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BIMAGRUMAB | CHEMBL3137353 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 5 | 4 | 4 | Drugs and targets |
| ARIMOCLOMOL | CHEMBL2107726 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| SIROLIMUS | CHEMBL413 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ULVIPRUBART | CHEMBL4650433 | Antibody | Phase 2/3 | ClinicalTrials.gov and TTD | 5 | 3 | 3 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INFLIXIMAB | CHEMBL1201581 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALEMTUZUMAB | CHEMBL1201587 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GARETOSMAB | CHEMBL4298176 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets16
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| C5 | Complement C5 | 2 | Complement C5 inhibitor; Complement C5 mRNA RNAi inhibitor | Early phase 1 | https://conductscience.org/library/genes/727 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 2/3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| ACVR2B | Activin receptor type-2B | 1 | Activin receptor type-2B antagonist | Phase 3 | https://conductscience.org/library/genes/93 | Drugs and targets |
| CD52 | CAMPATH-1 antigen | 1 | CAMPATH-1 antigen inhibitor | Phase 2 | https://conductscience.org/library/genes/1043 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| INHBA | Inhibin beta A chain | 1 | Inhibin beta A chain inhibitor | Phase 2 | https://conductscience.org/library/genes/3624 | Drugs and targets |
| ITGA4 | Integrin alpha-4/beta-1 | 1 | Integrin alpha-4/beta-1 inhibitor; Integrin alpha-4/beta-7 inhibitor | Phase 1 | https://conductscience.org/library/genes/3676 | Drugs and targets |
| ITGB1 | Integrin alpha-4/beta-1 | 1 | Integrin alpha-4/beta-1 inhibitor | Phase 1 | https://conductscience.org/library/genes/3688 | Drugs and targets |
| ITGB7 | Integrin alpha-4/beta-7 | 1 | Integrin alpha-4/beta-7 inhibitor | Phase 1 | https://conductscience.org/library/genes/3695 | Drugs and targets |
1 to 10 of 16
See all 16 targetsTrials21
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01925209 | Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients | Phase 2/3 | 251 | 2017-05-12 | Sporadic Inclusion Body Myositis | BIMAGRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02573467 | An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 | Phase 3 | 211 | 2018-03-13 | Sporadic Inclusion Body Myositis | BIMAGRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02753530 | Study of Arimoclomol in Inclusion Body Myositis (IBM) | Phase 2 | 152 | 2023-05-10 | Inclusion Body Myositis | ARIMOCLOMOL | Its record names the disease | ClinicalTrials.gov |
| NCT04049097 | Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial | Phase 3 | 121 | 2023-09-15 | Inclusion Body Myositis | ARIMOCLOMOL | Its record names the disease | ClinicalTrials.gov |
| NCT00769860 | Arimoclomol in Sporadic Inclusion Body Myositis | Phase 2/3 | 24 | 2017-01-19 | Inclusion Body Myositis | ARIMOCLOMOL | Its record names the disease | ClinicalTrials.gov |
| NCT02250443 | Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis | Phase 2/3 | 10 | 2018-04-10 | Sporadic Inclusion Body Myositis (sIBM) | BIMAGRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05721573 | A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis | Phase 2/3 | 272 | Inclusion Body Myositis | ULVIPRUBART | Its record names the disease | ClinicalTrials.gov | |
| NCT06450886 | Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis | Phase 2/3 | 270 | Inclusion Body Myositis (IBM) | ULVIPRUBART | Its record names the disease | ClinicalTrials.gov | |
| NCT04789070 | Phase III Trial of Sirolimus in IBM | Phase 3 | 140 | Inclusion Body Myositis | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT06536166 | Ruxolitinib Treatment in Inclusion Body Myositis | Phase 2 | 80 | Inclusion Body Myositis, Sporadic | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 21
See all 21 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arimoclomol (20 Months) vs Placebo (20 Months): deaths from any cause | 1 of 73 | 1 of 78 | 151 | NCT02753530 | Trial comparisons |
| Arimoclomol (20 Months) vs Placebo (20 Months): serious adverse events | 11 of 73 | 18 of 78 | 151 | NCT02753530 | Trial comparisons |
| Arimoclomol vs Placebo: serious adverse events | 0 of 16 | 1 of 8 | 24 | NCT00769860 | Trial comparisons |
Papers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007827
GET https://conductscience.org/api/diseases/v1/MONDO_0007827/trials?page=2